In the editorial, "Reflections on FDA Warning to 23andMe," Evans explains why the U.S. Food and Drug Administration (FDA) did the right thing by cracking down on the Internet-based genetic testing company, which advertised medical benefits to customers who had used their testing kit.
“The bottom line is that genomic analysis is a complex medical test with the power to help, to harm, and to confuse. The FDA was simply acting within its mandate and made a reasonable demand regarding 23andMe’s product: show us the data in support of your claims. The company couldn’t do that, so the FDA took the logical next step. When I buy a toaster I expect it to live up to the claims that have been made. Why should we expect anything less for something advertised as a medical test?” wrote Evans.
Evans is the Director of the Cancer Genetics Program and is a member of the UNC Lineberger Comprehensive Cancer Center.
To read more, visit The Cancer Letter website here.